| scholarly article | Q13442814 |
| P50 | author | Antonella Caputo | Q56810196 |
| Barbara Ensoli | Q21255143 | ||
| P2093 | author name string | Aurelio Cafaro | |
| Cinzia Fortini | |||
| Arianna Bottoni | |||
| Alessandro Canella | |||
| Mauro Marastoni | |||
| Paola Rimessi | |||
| Marina Fabris | |||
| Riccardo Gavioli | |||
| Eleonora Gallerani | |||
| Angela Bonaccorsi | |||
| Fabiola Micheletti | |||
| P2860 | cites work | Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line | Q29547239 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cytotoxicity | Q246181 |
| P304 | page(s) | 3838-3843 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity | |
| P478 | volume | 173 |
| Q44280840 | A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. |
| Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
| Q42816220 | Abnormal IFN-gamma-dependent immunoproteasome modulation by Trypanosoma cruzi-infected macrophages |
| Q39454661 | Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1. |
| Q33916162 | An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge |
| Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
| Q36673300 | Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions |
| Q30356937 | Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. |
| Q31010282 | CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope |
| Q42206015 | Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire |
| Q61641053 | Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin |
| Q64259098 | Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study |
| Q57373962 | DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination |
| Q38533881 | Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine |
| Q37047159 | Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition |
| Q43880475 | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant |
| Q61641083 | Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag |
| Q38059499 | Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells |
| Q28291410 | Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP |
| Q36479939 | Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins |
| Q41846314 | HIV Tat-mediated transcriptional regulation of proteasome protein cleavage specificity. |
| Q83364941 | HIV fragment gag vaccine induces broader T cell response in mice |
| Q35552889 | HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial |
| Q36109585 | HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology |
| Q33613221 | HIV-1 Tat regulates cyclin B1 by promoting both expression and degradation |
| Q30381447 | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. |
| Q46346144 | HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently |
| Q34374375 | HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses |
| Q40369481 | HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. |
| Q34477471 | HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies |
| Q36986644 | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial |
| Q38177328 | Harnessing proteasome dynamics and allostery in drug design. |
| Q37247915 | Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation |
| Q47738688 | Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration |
| Q41925734 | Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. |
| Q38264766 | Isolation and purification of proteasomes from primary cells |
| Q26866505 | Mechanisms of HIV protein degradation into epitopes: implications for vaccine design |
| Q39985578 | Modulation of immunoproteasome subunits by liposomal lipid A. |
| Q37509718 | Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications |
| Q41876665 | Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. |
| Q37419985 | Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses |
| Q34481984 | Nucleolar protein trafficking in response to HIV-1 Tat: rewiring the nucleolus |
| Q41144784 | Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function |
| Q33649755 | Patterns of HIV-1 protein interaction identify perturbed host-cellular subsystems |
| Q60243630 | Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes |
| Q47776137 | Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice |
| Q36758574 | Problems and emerging approaches in HIV/AIDS vaccine development |
| Q39588027 | Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells. |
| Q36489392 | Reciprocal transactivation between HIV-1 and other human viruses |
| Q36416882 | SjTat-TPI facilitates adaptive T-cell responses and reduces hepatic pathology during Schistosoma japonicum infection in BALB/c mice |
| Q40745814 | Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection |
| Q39130522 | Tat is a multifunctional viral protein that modulates cellular gene expression and functions |
| Q56897975 | Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability |
| Q35040673 | The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses |
| Q61641064 | The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS |
| Q37364423 | The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice |
| Q33864926 | The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study |
| Q38378021 | The preventive phase I trial with the HIV-1 Tat-based vaccine |
| Q28476094 | Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART |
Search more.